BLAINJECTIONSOLUTION
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STIMUFEND (pegfilgrastim-fpgk) is a long-acting granulocyte colony-stimulating factor (G-CSF) biosimilar approved by the FDA in September 2022. It is a cytokine injection indicated for reducing the duration of neutropenia and associated complications in patients receiving myelosuppressive chemotherapy. The drug works by stimulating the proliferation and differentiation of neutrophil progenitor cells to increase white blood cell count.
Peak
Product is in peak commercial phase with moderate competitive pressure (30); team size and growth trajectory dependent on Fresenius Kabi's biosimilar expansion strategy.
Mechanism of Action
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Only one linked job posting is available for STIMUFEND, concentrated in Regulatory Affairs and legal functions. This suggests early-stage or specialized hiring activity, likely tied to post-approval compliance, market access, or biosimilar-specific regulatory strategy rather than broad commercial buildout.
Corporate Counsel
Worked on STIMUFEND at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.